Findings from the BEACON (Binimetinib, Encorafenib, And Cetuximab cOmbiNed) clinical trial resulted in the standard of care for patients with refractory metastatic BRAFV600E CRC becoming combined BRAF (encorafenib) and epidermal growth factor receptor (EGFR; cetuximab) inhibition [2]. Here, BRAF is linked to colorectal carcinoma.